[Successful treatment of relapse/refractory multiple myeloma with carfilzomib, lenalidomide, and dexamethasone combination therapy following allogeneic bone marrow transplantation]

Rinsho Ketsueki. 2019;60(10):1468-1470. doi: 10.11406/rinketsu.60.1468.
[Article in Japanese]

Abstract

A 50-year-old male was diagnosed with multiple myeloma (MM) and treated by high-dose melphalan followed by autologous stem cell transplantation in April 2014. However, he relapsed and received non-myeloablative bone marrow transplantation from an unrelated HLA-matched donor (UR-BMT) in July 2016. After 100 days of UR-BMT, the disease remained stable disease and the patient was treated with carfilzomib, lenalidomide, and dexamethaonse (KRd) therapy. After 10 cycles of KRd, he obtained stringent complete response without exacerbation of graft-versus-host disease. We concluded that KRd after allogeneic stem cell transplantation is one of the useful treatment regimens for relapsed refractory MM.

Keywords: Allogeneic stem cell transplantation; Carfilzomib; Lenalidomide; Multiple myeloma.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols*
  • Bone Marrow Transplantation
  • Dexamethasone / therapeutic use*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Lenalidomide / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Myeloma / therapy*
  • Neoplasm Recurrence, Local
  • Oligopeptides / therapeutic use*
  • Transplantation, Autologous

Substances

  • Oligopeptides
  • carfilzomib
  • Dexamethasone
  • Lenalidomide